{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:25:49Z","timestamp":1725755149545},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,7]]},"DOI":"10.7759\/cureus.68868","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T13:24:44Z","timestamp":1725715484000},"source":"Crossref","is-referenced-by-count":0,"title":["Split-Course Adaptive Radioimmunotherapy for Oligometastatic Non-Small Cell Lung Cancer (SiCARIO): A Case Report"],"prefix":"10.7759","author":[{"given":"Kyra N","family":"McComas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E","family":"Masick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D","family":"Yock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert C","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020, 11:3801. 10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0230","article-title":"Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy","volume":"17","author":"Stenehjem D","year":"2021","unstructured":"Stenehjem D, Lubinga S, Betts KA, et al.. Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. Future Oncol. 2021, 17:2940-9. 10.2217\/fon-2021-0230","journal-title":"Future Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck M","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019, 37:537-46. 10.1200\/JCO.18.00149","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum RR","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison?. Nat Rev Clin Oncol. 2017, 14:365-79. 10.1038\/nrclinonc.2016.211","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia SJ","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, et al.. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018, 379:2342-50. 10.1056\/NEJMoa1809697","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-1528","article-title":"The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review","volume":"10","author":"Turchan WT","year":"2021","unstructured":"Turchan WT, Chmura SJ. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med. 2021, 10:6028-44. 10.21037\/apm-20-1528","journal-title":"Ann Palliat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box C","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, et al.. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017, 8:15618. 10.1038\/ncomms15618","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1118\/1.3215532","article-title":"An on-line replanning method for head and neck adaptive radiotherapy","volume":"36","author":"Ahunbay EE","year":"2009","unstructured":"Ahunbay EE, Peng C, Godley A, Schultz C, Li XA. An on-line replanning method for head and neck adaptive radiotherapy. Med Phys. 2009, 36:4776-90. 10.1118\/1.3215532","journal-title":"Med Phys"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/42\/1\/008","article-title":"Adaptive radiation therapy","volume":"42","author":"Yan D","year":"1997","unstructured":"Yan D, Vicini F, Wong J, Martinez A. Adaptive radiation therapy. Phys Med Biol. 1997, 42:123-32. 10.1088\/0031-9155\/42\/1\/008","journal-title":"Phys Med Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.10.021","article-title":"Adaptive radiation therapy (ART) strategies and technical considerations: a state of the ART review from NRG Oncology","volume":"109","author":"Glide-Hurst CK","year":"2021","unstructured":"Glide-Hurst CK, Lee P, Yock AD, et al.. Adaptive radiation therapy (ART) strategies and technical considerations: a state of the ART review from NRG Oncology. Int J Radiat Oncol Biol Phys. 2021, 109:1054-75. 10.1016\/j.ijrobp.2020.10.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.2038","article-title":"Dosimetric benefits of online adaptive radiotherapy in nasopharyngeal carcinoma","volume":"117","author":"Yang YX","year":"2023","unstructured":"Yang YX, Zhou GQ, Lin L, et al.. Dosimetric benefits of online adaptive radiotherapy in nasopharyngeal carcinoma. Int J Rad Oncol Biol Phys. 2023, 117:635-636. 10.1016\/j.ijrobp.2023.06.2038","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13425","article-title":"Initial analysis of the dosimetric benefit and clinical resource cost of CBCT-based online adaptive radiotherapy for patients with cancers of the cervix or rectum","volume":"22","author":"Yock AD","year":"2021","unstructured":"Yock AD, Ahmed M, Ayala-Peacock D, Chakravarthy AB, Price M. Initial analysis of the dosimetric benefit and clinical resource cost of CBCT-based online adaptive radiotherapy for patients with cancers of the cervix or rectum. J Appl Clin Med Phys. 2021, 22:210-21. 10.1002\/acm2.13425","journal-title":"J Appl Clin Med Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.075","article-title":"SiCARIO: a phase I\/II study of split-course adaptive radioimmunotherapy for the treatment of oligometastatic non-small cell lung cancer (NSCLC) using adaptive radiotherapy","volume":"118","author":"Whitaker RM","year":"2024","unstructured":"Whitaker RM, Osmundson EC. SiCARIO: a phase I\/II study of split-course adaptive radioimmunotherapy for the treatment of oligometastatic non-small cell lung cancer (NSCLC) using adaptive radiotherapy. Int J Rad Oncol Biol Phys. 2024, 118:e15. 10.1016\/j.ijrobp.2023.10.075","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst RS","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018, 553:446-54. 10.1038\/nature25183","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1214265","article-title":"Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer","volume":"16","author":"Yang J","year":"2016","unstructured":"Yang J, Chen J, Wei J, Liu X, Cho WC. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opin Biol Ther. 2016, 16:1209-23. 10.1080\/14712598.2016.1214265","journal-title":"Expert Opin Biol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2019.11.002","article-title":"Targeted therapy and checkpoint immunotherapy in lung cancer","volume":"13","author":"Ruiz-Cordero R","year":"2020","unstructured":"Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020, 13:17-33. 10.1016\/j.path.2019.11.002","journal-title":"Surg Pathol Clin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou VK","year":"2015","unstructured":"Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 2015, 21:976-84. 10.1158\/1078-0432.CCR-14-1187","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma DA","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019, 393:2051-2058. 10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02222-7","article-title":"Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer","volume":"18","author":"Hoppen L","year":"2023","unstructured":"Hoppen L, Sarria GR, Kwok CS, et al.. Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer. Radiat Oncol. 2023, 18:34. 10.1186\/s13014-023-02222-7","journal-title":"Radiat Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.2273","article-title":"Dosimetric impact of simulated daily adaptive radiotherapy with significantly reduced setup margins in the definitive treatment of head and neck cancer","volume":"114","author":"Dohopolski M","year":"2022","unstructured":"Dohopolski M, Choi B, Meng B, et al.. Dosimetric impact of simulated daily adaptive radiotherapy with significantly reduced setup margins in the definitive treatment of head and neck cancer. Int J Rad Oncol Biol Phys. 2022, 114:e590. 10.1016\/j.ijrobp.2022.07.2273","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.08.032","article-title":"Acute toxicity and efficiency outcomes in the DARTBOARD randomized trial of daily adaptive radiotherapy for head and neck squamous cell carcinoma","volume":"117","author":"Sher DJ","year":"2023","unstructured":"Sher DJ, Avkshtol V, Lin MH, et al.. Acute toxicity and efficiency outcomes in the DARTBOARD randomized trial of daily adaptive radiotherapy for head and neck squamous cell carcinoma. Int J Rad Oncol Biol Phys. 2023, 117:e6. 10.1016\/j.ijrobp.2023.08.032","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109538","article-title":"Same-day adaptive palliative radiotherapy without prior CT simulation: Early outcomes in the FAST-METS study","volume":"182","author":"Nelissen KJ","year":"2023","unstructured":"Nelissen KJ, Versteijne E, Senan S, et al.. Same-day adaptive palliative radiotherapy without prior CT simulation: Early outcomes in the FAST-METS study. Radiother Oncol. 2023, 182:109538. 10.1016\/j.radonc.2023.109538","journal-title":"Radiother Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281434-split-course-adaptive-radioimmunotherapy-for-oligometastatic-non-small-cell-lung-cancer-sicario-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T13:24:46Z","timestamp":1725715486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281434-split-course-adaptive-radioimmunotherapy-for-oligometastatic-non-small-cell-lung-cancer-sicario-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.68868","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2024,9,7]]}}}